Method for the treatment of patients with carcinomas

The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS...

Full description

Saved in:
Bibliographic Details
Main Authors Chao García, Lisset, Hernández Fernández, Diana Rosa, González Suárez, Narjara, Sánchez Ramírez, Belinda, Báez Bergado, Gretchen, Cruz Rodríguez, Mabel
Format Patent
LanguageEnglish
Published 25.06.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS activating mutations. In particular, this method is based on the application of bivalent vaccine compositions which have as active principle the extracellular domains of the HER1 and HER2 receptors or portions thereof and as an adjuvant the very small proteoliposomes derived from the outer membrane proteins of Neisseria meningitidis and the GM3 ganglioside. This method is useful for the treatment of patients whose expression levels of HER1 and HER2 do not allow the monoclonal antibodies against HER1 and/or HER2 to have a therapeutic effect.
Bibliography:Application Number: US201816494102